JP2017523188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523188A5 JP2017523188A5 JP2017504752A JP2017504752A JP2017523188A5 JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5 JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- use according
- modification
- amino acid
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US62/032,430 | 2014-08-01 | ||
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US62/119,668 | 2015-02-23 | ||
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| US62/127,484 | 2015-03-03 | ||
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523188A JP2017523188A (ja) | 2017-08-17 |
| JP2017523188A5 true JP2017523188A5 (enExample) | 2018-09-13 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504752A Pending JP2017523188A (ja) | 2014-08-01 | 2015-07-31 | Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160032404A1 (enExample) |
| EP (1) | EP3185870A4 (enExample) |
| JP (1) | JP2017523188A (enExample) |
| KR (1) | KR20170042614A (enExample) |
| CN (1) | CN106714804A (enExample) |
| AU (1) | AU2015296010A1 (enExample) |
| BR (1) | BR112017001677A2 (enExample) |
| CA (1) | CA2955744A1 (enExample) |
| IL (1) | IL250221A0 (enExample) |
| MX (1) | MX2017001302A (enExample) |
| RU (1) | RU2017106794A (enExample) |
| SG (1) | SG11201700774UA (enExample) |
| WO (1) | WO2016019341A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| ME03010B (me) | 2008-10-22 | 2018-10-20 | Array Biopharma Inc | Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
| CA3113343C (en) | 2010-06-03 | 2024-10-08 | Pharmacyclics Llc | USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| KR102632745B1 (ko) | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| DK3439662T3 (da) | 2016-04-04 | 2024-09-02 | Loxo Oncology Inc | Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| JP7356351B2 (ja) * | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム |
| CN110382439A (zh) | 2016-12-30 | 2019-10-25 | 埃克切拉生物科学公司 | 多级样品回收系统 |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110996972A (zh) * | 2017-06-08 | 2020-04-10 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的治疗性凋亡细胞 |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| EA202190045A1 (ru) * | 2018-06-15 | 2021-03-17 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ибрутиниб |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| JP2022513666A (ja) * | 2018-11-30 | 2022-02-09 | ヤンセン バイオテツク，インコーポレーテツド | 濾胞性リンパ腫の治療方法 |
| EP3890876B1 (en) | 2018-12-06 | 2024-05-01 | Xcella Biosciences, Inc. | Lateral loading of microcapillary arrays |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| WO2022169731A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| US20230010803A1 (en) * | 2021-06-30 | 2023-01-12 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| JP2024526241A (ja) * | 2021-06-30 | 2024-07-17 | ヤンセン ファーマシューティカ エヌ．ベー． | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| WO2025080543A1 (en) * | 2023-10-09 | 2025-04-17 | Bristol-Myers Squibb Company | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| JP7696987B1 (ja) * | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113343C (en) * | 2010-06-03 | 2024-10-08 | Pharmacyclics Llc | USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA |
| US20130102477A1 (en) * | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| BR112014009276A8 (pt) * | 2011-10-19 | 2017-06-20 | Pharmacyclics Inc | uso de inibidores de tirosina quinase de bruton (btk) |
| AR088570A1 (es) * | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| KR20150015021A (ko) * | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| US10954567B2 (en) * | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| WO2014110114A1 (en) * | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2015
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523188A5 (enExample) | ||
| RU2017106794A (ru) | Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| Wang et al. | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies | |
| EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
| MY185845A (en) | Icos binding proteins | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| EP3423664A4 (en) | ADJUSTING MECHANISMS, MANAGING THEM AND RELATED METHODS | |
| JP2014523751A5 (enExample) | ||
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| WO2017027571A8 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| WO2017116817A3 (en) | Testing of medicinal drugs and drug combinations | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| EP3869198A3 (en) | Reagents and methods for breast cancer detection | |
| EA202092156A1 (ru) | Модифицированные олигонуклеотиды и способы применения в лечении таупатий | |
| JP2017506259A5 (enExample) | ||
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| TWD195924S (zh) | 寶石 | |
| JP2015504432A5 (enExample) | ||
| CN109562093A (zh) | 含peitc的药物组合物及其在癌症治疗中的应用 | |
| SG10201903424RA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| Ling et al. | Re: Gut microbiota depletion from early adolescence in mice: Implications for brain and behavior | |
| CO2019002853A2 (es) | Composiciones de tesofensina | |
| EP3733861A4 (en) | IN VITRO PROTEIN SYNTHESIS SYSTEM, KIT AND ITS PREPARATION PROCESS | |
| PAUL | An In-depth Description and Detailed Analysis of Implementing Alternative Methods of Financing Software |